Oral drug absorption and the biopharmaceutics classification system

Journal of Drug Delivery Science and Technology

Volumn 17, Issue 4, 2007, Pages 237-244

  Lennernas H ^a   Abrahamsson, B ^a   Persson, E M ^a   Knutson, L ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Bioavailability; Bioequivalence; Biopharmaceutics Classification System

Indexed keywords

AMILORIDE; AMOXICILLIN; ATENOLOL; CARBAMAZEPINE; CEFALEXIN; CIMETIDINE; DESIPRAMINE; ENALAPRIL MALEATE; ENALAPRILAT; FEXOFENADINE; FLUINDOSTATIN; FUROSEMIDE; HYDROCHLOROTHIAZIDE; KETOPROFEN; LEVODOPA; LISINOPRIL; LOSARTAN POTASSIUM; METHYLDOPA; METOPROLOL TARTRATE; NAPROXEN; PHENAZONE; PIROXICAM; PROPRANOLOL; RANITIDINE; TERBUTALINE; VALACICLOVIR; VERAPAMIL;

BIOEQUIVALENCE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; DRUG SOLUBILITY; HUMAN; INTESTINE ABSORPTION; REVIEW;

EID: 34548585785     PISSN: 17732247     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1773-2247(07)50090-0     Document Type: Review

References (51)

1. Prentis R.A., Lis Y., Walker S.R. - Pharmaceutical innovation by the seven UK owned pharmaceutical companies (1964-1985). - Br. J. Clin. Pharmacol., 25, 387-396, 1988.
2. Frank R., Hargreaves R. - Clinical biomarkers in drug discovery and development. - Nat. Rev. Drug Discov., 2 (7), 566-580, 2003.
3. Van de Waterbeemd H., Smith D.A., Beaumont K., Walker D.K. - Property-based design: optimization of drug absorption and pharmacokinetics. - J. Med. Chem., 44, 1313-1333, 2001.
4. Amidon G.L., Lennernäs H., Shah V.P., Crison J.R. - A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. - Pharm Res, 12, 413-420, 1995.
5. Lennernäs H., Abrahamsson B. - The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension. - J. Pharm. Pharmacol., 57, 273-285, 2005.
6. Kasim N.A., Whitehouse M., Ramachandran C., Bermejo M., Lennernäs H., Hussain A.S., Junginger H.E., Stavchansky S.A., Midha K.K., Shah V.P., Amidon G.L. - Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. - Mol. Pharm., 12, 85-96, 2004.
7. Yazdanian M., Briggs K., Jankovsky C., Hawi A. - The "high solubility" definition of the current FDA guidance on biopharmaceutical classification system may be too strict for acidic drugs. - Pharm. Res., 21, 293-299, 2004.
8. Yu L.X., Ellison C.D., Conner D.P., Lesko L.J., Hussain A.S. - Influence of drug release properties of conventional solid dosage forms on the systemic exposure of highly soluble drugs. - AAPS Pharm. Sci., 3, E24, 2001.
9. Dressman J.B., Amidon G.L., Reppas C., Shah V.P. - Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. - Pharm. Res., 15, 11-22, 1998.
10. Polli J.E., Yu L.X., Cook J.A., Amidon G.L., Borchardt R.T., Bumside B.A., Burton P.S., Chen M.L., Conner D.P., Faustino P.J., Hawi A.A., Hussain A.S., Joshi H.N., Kwei G., Lee V.H., Lesko L.J., Upper R.A., Loper A.E., Nerurkar S.G., Polli J.W., Sanvordeker D.R., Taneja R., Uppoor R.S., Vattikonda C.S., Wilding I., Zhang G. - Summary workshop report: Biopharmaceutics classification system - implementation challenges and extension opportunities. - J. Pharm. Sci., 93, 1375-1381, 2004.
11. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. - Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. - Adv. Drug Deliv. Rev., 46, 3-26, 2001.
12. Winiwarter S., Bonham N., Hallberg A., Lennernäs H., Karlén A. - Correlation of human jejunal permeability (in vivo) with experimentally and theoretically derived parameters. A multivariate data analysis approach. - J. Med. Chem., 41, 4939-4949, 1999.
13. Winiwarter S., Ax F., Lennernäs H., Hallberg A., Pettersson C., Karlén A. - Hydrogen bonding descriptors in the prediction of human in vivo intestinal permeability. - J. Mol. Graph. Model., 21, 283-287, 2003
14. Agoram B., Woltosz W.S., Bolger M.B. - Predicting the impact of physiological and biochemical processes on oral drug bioavailability. - Adv. Drug Deliv. Rev., 50, Suppl 1, S41-67, 2001.
15. Lennernäs H. - Intestinal drug absorption and bioavailability: beyond involvement of single transport function. - J. Pharm. Pharmacol., 55, 429-433, 2003
16. Nakamura T., Sakaeda T., Ohmoto N., Tamura T., Aoyama N., Shirakawa T., Kamigaki T., Nakamura T., Kim K.I., Kim S.R., Kuroda Y., Matsuo M., Kasuga M., Okumura K. - Real-time quantitative polymerase chain reaction for MDR1, MRP1, MRP2, and CYP3A-mRNA levels in Caco-2 cell lines, human duodenal enterocytes, normal colorectal tissues, and colorectal adenocarcinomas. - Drug Metab. Dispos., 30, 4-6, 2002.
17. Berggren S., Gall C., Wollnitz N., Ekelund M., Karlbom U., Hoogstraate J., Schrenk D., Lennernäs H. - Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine. - Mol. Pharm., 2007 Jan 31; [Epub ahead of print], 2007
18. Lennernäs H. - Human intestinal permeability: an overview - J. Pharm. Sci., 87, 403-410, 1998.
19. Lennernäs H., Gjellan K., Hällgren R., Graffner C. - The influence of caprate on rectal absorption of phenoxymetylpenicillin: experience from an in vivo perfusion in humans. - J. Pharm. Pharmacol., 54, 499-508, 2002.
20. Lennernäs H., Nilsson D., Aquilonius S.-M., Ahrenstedt Ö., Knutson L., Paalzow L.K. - The effect of L-leucine on the absorption of levodopa, studied by regional jejunal perfusion in man. - Br. J. Clin. Pharmacol., 35, 243-250, 1993.
21. Lennernäs H., Knutson L., Knutson T., Hussain A., Lesko L. - The effect of amiloride on the in vivo effective permeability of amoxicillin in human jejunum: experience from a regional perfusion technique. - Eur. J. Pharm. Sci., 15, 271-277, 2002.
22. Lennernäs H., Ahrenstedt O., Hallgren R., Knutson L., Ryde M., Paalzow L.K. - Regional jejunal perfusion, a new in vivo approach to study oral drug absorption in man. - Pharm. Res., 9, 1243-1251, 1992.
23. Sun D., Lennernäs H., Welage L.S., Barnett J.L., Landowski C.P., Foster D., Fleisher D., Lee K.-D., Amidon G.L. - Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. - Pharm. Res., 19, 1400-1416, 2002.
24. Cao X., Gibbs S.T., Fang L., Miller H.A., Landowski C.P., Shin H.C., Lennernäs H., Zhong Y., Amidon G.L., Yu L.X., Sun D. - Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. - Pharm. Res., 23, 1675-86, 2006.
25. Sandström R., Karlsson A., Knutson L., Lennernäs H. - Jejunal absorption and metabolism of R/S-verapamil in humans. - Pharm. Res., 15, 856-562, 1998.
26. Sandström R., Knutson T.W., Knutson L., Jansson B., Lennernäs H. - The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R/S)-verapamil in humans. - Br. J. Clin. Pharmacol., 48, 180-189, 1999.
27. von Richter O., Greiner B., Fromm M.F., Fraser R., Omari T., Barclay M.L., Dent J., Somogyi A.A., Eichelbaum M. - Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion technique. - Clin. Pharmacol. Ther., 70, 217-227, 2001.
28. Wu C.Y., Benet L.Z., Hebert M.F., Gupta S.K., Rowland M., Gomez D.Y., Wacher V.J. - Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. - Clin. Pharmacol. Ther., 58, 492-497, 1995.
29. Van de Waterbeemd H., Gifford E. - ADMET in silico modelling: towards prediction paradise? - Nat. Rev. Drug Discov., 2, 192-204, 2003
30. Sun H. - A universal molecular descriptor system for prediction of logP, logS, logBB, and absorption. - J. Chem. Inf. Comput. Sci., 44, 748-757, 2004.
31. Scholz A., Kostewicz E., Abrahamsson B., Dressman J.B. - Can the USP paddle method be used to represent in vivo hydrodynamics? - J Pharm Pharmacol., 55, 443-451, 2003.
32. Persson E.M., Gustafsson A.S., Carlsson A.S., Nilsson R.G., Knutson L., Forsell P., Hanisch G., Lennernäs H., Abrahamsson B. - The effects of food on the dissolution of poorly soluble drugs in human and in model small intestinal fluids. - Pharm. Res., 22, 2141-2151, 2005.
33. Persson E.M., Nilsson R.G., Hansson G.I., Lofgren L.J., Liback F., Knutson L., Abrahamsson B., Lennernäs H. - A clinical single-pass perfusion investigation of the dynamic in vivo secretory response to a dietary meal in human proximal small intestine. - Pharm. Res., 23, 742-751, 2006.
34. Patravale V.B., Date A.A., Kulkarni R.M. - Nanosuspensions: a promising drug delivery strategy. - J. Pharm. Pharmacol., 56, 827-840, 2004.
35. Kossena G.A., Charman W.N., Boyd B.J., Dunstan D.E., Porter C.J. - Probing drug solubilization patterns in the gastrointestinal tract after administration of lipid-based delivery systems: a phase diagram approach. - J. Pharm. Sci., 93, 332-348, 2004.
36. Kostewicz E.S., Brauns U., Becker R., Dressman J.B. - Forecasting the oral absorption behavior of poorly soluble weak bases using solubility and dissolution studies in biorelevant media. - Pharm. Res., 19, 345-349, 2002.
37. Kostewicz E.S., Wunderlich M., Brauns U., Becker R., Bock T., Dressman J.B. - Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine. - J. Pharm. Pharmacol., 56, 43-51, 2004.
38. Lajiness M.S., Vieth M., Erickson J. - Molecular properties that influence oral drug-like behavior. - Curr. Opin. Drug Discov. Devel., 7, 470-457, 2004.
39. Abrahamsson B., Roos K., Sjogren J. - Investigation of prandial effects on hydrophilic matrix tablets. - Drug Dev. Ind. Pharm., 25, 765-71, 1999.
40. Kalantzi L., Persson E., Polentarutti B., Abrahamsson B., Goumas K., Dressman J.B., Reppas C. - Canine intestinal contents vs. simulated media for the assessment of solubility of two weak bases in the human small intestinal contents. - Pharm. Res., 23, 1373-81, 2006.
41. Weitschies W., Wedemeyer R.S., Kosch O., Fach K., Nagel S., Soderlind E., Trahms L., Abrahamsson B., Monnikes H. - Impact of the intragastric location of extended release tablets on food interactions. - J. Control. Release, 108, 375-85, 2005.
42. Abrahamsson B., Albery T., Eriksson A., Gustafsson I., Sjoberg M. - Food effects on tablet disintegration. - Eur. J. Pharm. Sci., 22, 165-72, 2004.
43. Pal A., Indireshkumar K., Schwizer W., Abrahamsson B., Fried M., Brasseur J.G. - Gastric flow and mixing studied using computer simulation. - Proc. Biol. Sci., 271, 2587-94, 2004.
44. Bonlokke L., Hovgaard L., Kristensen H.G., Knutson L., Lennernäs H. - Direct estimation of the in vivo dissolution of spironolactone, in two particle size ranges, using the single-pass perfusion technique (Loc-I-Gut) in humans. - Eur. J. Pharm. Sci., 12, 239-50, 2001.
45. Bates T.R., Gibaldi M., Kanig J.L. - Solubilizing propertied of bile salt solutions I. - J. Pharm. Sci., 55, 191-199 1966.
46. Bates T.R., Gibaldi, M., Kanig J.L. - Solubilizing propertied of bile salt solutions II. - J. Pharm. Sci., 55, 901-906 1966.
47. Bakatselou V., Oppenheim R.C., Dressman J.B. - Solubilization and wetting effects of bile salts on the dissolution of steroids. - Pharm. Res., 8, 1461-1469, 1991.
48. Nielsen P., Müllertz A., Norling T., Kristensen H.G. - The effect of alpha-tocopherol on the in vitro solubilization of lipophilic drugs. - Int. J. Pharm., 222, 217-224 2001.
49. Kossena G.A, Boyd B.J., Porter C.J., Charman W.N. - Separation and characterization of the colloidal phases produced on digestion of common formulation lipids and assessment of their impact on the apparent solubility of selected poorly water-soluble drugs. - J. Pharm. Sci., 92, 634-648, 2003.
50. Grove M., Pedersen G.P., Nielsen J.L., Müllertz A. - Bioavailability of seocalcitol I: Relating solubility in biorelevant media with oral bioavailability in rat-effect of medium and long chain triglycerides. - J. Pharm. Sci., 94, 1830-1838, 2005.
51. Skold C., Winiwarter S., Wernevik J., Bergstrom F., Engstrom L., Allen R., Box K., Comer J., Mole J., Hallberg A., Lennernäs H., Lundstedt T., Ungell A.L., Karlen A. - Presentation of a structurally diverse and commercially available drug data set for correlation and benchmarking studies. - J. Med. Chem., 49, 6660-6671, 2006.